Cancer-associated fibroblast
Cancer-associated fibroblasts (often abbreviated as CAF) are a type of cell that are present within the tumor microenvironment. They are one of the most abundant cell types in many types of cancer, and play a crucial role in cancer progression and metastasis.
Overview[edit]
Cancer-associated fibroblasts are derived from normal fibroblasts, which are cells that produce the structural framework (stroma) for animal tissues. In response to signals from cancer cells, fibroblasts can become permanently activated and transform into CAFs. These cells then contribute to the growth and spread of the tumor by secreting various growth factors, cytokines, and extracellular matrix proteins.
Role in Cancer Progression[edit]
CAFs play a key role in promoting tumor growth and metastasis. They do this through a variety of mechanisms, including:
- Stimulation of angiogenesis: CAFs secrete factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which promote the formation of new blood vessels. This provides the tumor with the nutrients it needs to grow.
- Promotion of cancer cell invasion: CAFs remodel the extracellular matrix and secrete enzymes that degrade the basement membrane, allowing cancer cells to invade surrounding tissues.
- Immune evasion: CAFs can suppress the immune response to the tumor by secreting immunosuppressive factors and attracting regulatory T cells.
Therapeutic Targeting of CAFs[edit]
Due to their crucial role in cancer progression, CAFs are being investigated as potential therapeutic targets. Strategies for targeting CAFs include inhibiting their activation, blocking their secreted factors, or depleting them from the tumor microenvironment. However, these approaches are still in the early stages of development and further research is needed to determine their efficacy and safety.
See Also[edit]
References[edit]
Cancer-associated fibroblast[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian